Abstracts tagged "Interleukins"

Abstract Number: 1448 • ACR Convergence 2025
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
Laure Gossec¹, Pascal Claudepierre², Arnaud Constantin³, Denis Jullien⁴, Samira Chaalal⁵, Julie Baraut⁵, Laure Cipiere⁵, Laurène Gautier⁶, Pierre Lemire⁷ and Thierry Passeron⁸, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Department of Rheumatology, CHU Henri Mondor, AP-HP, Créteil, France, Creteil, France, ³Department of Rheumatology, Toulouse University Hospital, Toulouse University and INSERM U¹²⁹¹, France, Toulouse, France, ⁴Hospices Civils de Lyon, Hôpital E. Herriot Department of Dermatologie, Lyon F-⁶⁹⁰⁰³ ; CIRI, Centre International de Recherche en Infectiologie, Team EIA : Epidermal immunity & Allergy, INSERM, U¹¹¹¹; Univ Lyon; Université de Lyon ¹; Ecole Normale Supérieure de Lyon; CNRS, UMR ⁵³⁰⁸, Lyon, France., Lyon, France, ⁵Johnson & Johnson, Issy les moulineaux, France, ⁶Johnson & Johson, Issy les Moulineaux, France, ⁷IQVIA, Real World Solutions, Paris, France, Paris, France, ⁸Johnson & Johnson, Nice, France
Background/Purpose: Psoriatic disease, including psoriasis (Pso) and psoriatic arthritis (PsA), seems to affect male and female patients differently in clinical presentation, disease progression and advanced…
Abstract Number: 0537 • ACR Convergence 2025
HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
Kent LE¹, Hervé LOCRELLE¹, Myriam NORMAND¹, Irina COMAN¹, Louis DELENTE¹, Tiphany NEEL¹, Adamah AMOUZOUGAN¹, Thierry THOMAS¹ and Hubert Marotte², ¹Service Rhumatologie Hôpital Nord, Saint-Etienne, France, ²INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France
Background/Purpose: To assess the prevalence, risk factors and treatment-related outcomes of uveitis in patients with spondyloarthritis (SpA), using data from a 15-year real-life cohort.Methods: We…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 1444 • ACR Convergence 2025
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Jeffrey Curtis¹, Genevieve Gauthier², Lara Fallon³, David Gruben³, You-Li Ling⁴, Matthew Brouillette³, Arne Yndestad⁵, Yu hong⁶ and Mona Kelkar⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ³Pfizer Inc, New York, NY, USA, New York, ⁴Pfizer Inc, New York, NY, USA, New York, NY, ⁵Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁶Genesis Research Group, Hoboken, NJ, USA, New York
Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…
Abstract Number: 2689 • ACR Convergence 2025
Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
April Armstrong¹, Joseph Merola², Gang Wang³, Ariane Faucher⁴, Riley Taiji⁴, Francis Vekeman⁴, Alexis Shew⁵, Tim Nguyen⁵ and Laura Coates⁶, ¹University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ²UT Southwestern Medical Center, Dallas, TX, ³Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China (People's Republic), ⁴STATLOG, Inc, Montreal, QC, Canada, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Biologic therapies for moderate to severe psoriasis (PsO) include inhibitors of IL-17 (IL-17i), IL-23i, IL-12/23i, and tumor necrosis factor (TNFi). Previous studies that assessed…
Abstract Number: 1441 • ACR Convergence 2025
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Hongbin Li¹ and Huilin Li², ¹Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), ²Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)
Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…
Abstract Number: 0486 • ACR Convergence 2025
Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Hideto Kameda¹, Sadatomo Tasaka², Toshiya Takahashi³, Naoki Soeda³, Katsuhisa Suzuki⁴ and Yoshiya Tanaka⁵, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ⁴Medical Affairs, Sanofi K.K., Tokyo, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Sarilumab (SAR) is approved as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for treatment of patients (pts) with moderate-to-severely active…
Abstract Number: 2576 • ACR Convergence 2025
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
Alfonso Sucerquia¹, Jose Forero², Juan Alzate¹, Adrienne Poon³, Gary Firestein⁴, Larry Moreland⁵, Andres Cadena⁶, Jose Lara⁶, Octavio pizarro⁶, Jesus Godoy⁶, Liliana Encinales⁷, David Boyle⁸, Evelyn Mendoza⁹, Carlos Herrera¹⁰ and Aileen Chang³, ¹The George Washington University, Arlington, ²The George Washington University, Arlington, VA, ³The George Washington University, Washington, ⁴University of California, San Diego, San Diego, CA, ⁵University of Colorado, Denver, CO, ⁶Clinica de la Costa, Barranquilla, Colombia, ⁷Allied Research Society, Barranquilla, Colombia, ⁸University of California, San Diego, San Diego, ⁹Universidad Libre de Barranquilla, Barranquilla, Colombia, ¹⁰The George Washington University, Alexandria
Background/Purpose: The MARCH study evaluates the efficacy of methotrexate monotherapy in patients with chikungunya-associated arthritis and aims to elucidate its pathologic mechanism via cytokine analysis.…
Abstract Number: 1423 • ACR Convergence 2025
Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
Meghna Gavali¹, Husna Fatima², Bhavya Sirivelu³, Nishanth S³ and Noorjahan M³, ¹nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ²Nizami Institute of Medical Sciences, Hyderabad, Telangana, India, ³Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder primarily affecting the axial skeleton and associated with HLA-B27. Non-HLA genes, including ERAP1 (Endoplasmic Reticulum Aminopeptidase…
Abstract Number: 0485 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Rheumathoid Arthritis (RA) is a chronic inflammatory disease that affects the musculoskeletal system. Early and effective treatment is important to improve the quality of…
Abstract Number: 2373 • ACR Convergence 2025
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Rocio Gonzalez Molina¹, BEATRIZ JOVEN², Marta Llanes³, Vanesa Hernandez⁴, Manuel Jose Moreno⁵, Elena Blanco⁶, Carolina Marin⁷, Lourdes Mateo⁸, Meritxell Salles Lizarzaburu⁹, Martina Steiner¹⁰, Laura Nuño¹¹, Antonio Fernández-Nebro¹², raúl Veroz González¹³, ana Urruticoechea-Arana¹⁴, Evelin Cervantes¹⁵, emilio Giner¹⁶, Lola Fernandez de la fuente Burson¹⁷, Alba Erra¹⁸, Oscar Camacho¹⁹, Elisabet Garcia²⁰, Angeles Hernandez²¹, Janire Malave²², Laia Orpinell²³, Inmaculada Ros Vilamajo²⁴, Sonia Castro²⁵, Patricia Lopez Viejo²⁶, Luis Sarabia²⁷, Rosa María García Portales²⁸, Jorge Cabezon²⁹, Puerto Moreno Gil³⁰, Francisco Maceiras³¹, Daniel Pielfort³², Sabela Diaz-Castroverde³³, Manuel Cuervas-mons³³, Jose Pinto-Tasende³⁴, Santiago Muñoz³⁵ and Julio Ramirez³⁶, ¹Hospital Reina Sofía, Murcia, Spain, ²H. Universitario ¹² Octubre, Madrid, Spain, ³H Juan Ramón Jimenez, Huelva, Spain, ⁴Hospital Universitario Canarias, Tenerife, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, El Palmar Murcia, Spain, ⁶Hospital Virgen del Rocio, Sevilla, Spain, ⁷Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁸Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ⁹Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Rheumatology. Hospital de Mérida. Mérida, Spain., Mérida, Spain, ¹⁴Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ¹⁵Hospital Provincial de Pontevedra, Pontevedra, Spain, ¹⁶Hospital Royo Vilanova, Zaragoza, Spain, ¹⁷Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁸Hospital Vall d´Hebron, Barcelona, Spain, ¹⁹Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²⁰Hospital Mollet, Barcelona, Spain, ²¹Hospital Naval, A Coruña, Spain, ²²Hospital Virgen del Puerto, Caceres, Spain, ²³Hospital Universitari Sagrat Cor, Barcelona, Spain, ²⁴Hospital Son Llàtzer, Palma de Mallorca, Spain, ²⁵ALTHAIA Hospital Sant Joan de Deu, Barcelona, Spain, ²⁶Hospital Universitario Getafe, Getafe, Spain, ²⁷Complejo Hospitalario de Jaén, Jaén, Spain, ²⁸HOSP. UNIVERSITARIO VIRGEN DE LA VICTORIA, Malaga, Spain, ²⁹HOSP. PUNTA DE EUROPA, Algeciras, Spain, ³⁰HOSPITAL SAN PEDRO DE ALCANTARA, Caceres, Spain, ³¹HOSPITAL DO MEIXOEIRO, Vigo, Spain, ³²Hospital General Universitario de Toledo, Toledo, Spain, ³³Johnson and Johnson, Madrid, Spain, ³⁴Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ³⁶Clinic Barcelona Hospital Universitari, Barcelona, Catalonia, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease affecting joints, entheses, skin, nails, and spine. While treatment options have expanded, TNF inhibitors (TNFis) remain the…
Abstract Number: 1353 • ACR Convergence 2025
Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
Gerd Burmester¹, Hiroaki Matsuno², Ernest Choy³, Masato Okada⁴, Roshan Dias⁵, Károly Horvát-Karajz⁵, Gordana Dancer⁵, Yusuke Karibe⁶, Suguru Masuda⁶, Joachim Kiefer⁵ and Paul Emery⁷, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Matsuno Clinic for Rheumatic Disease, Toyama, and Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Gedeon Richter Plc, Budapest, Hungary, ⁶Mochida Pharmaceutical Co., Ltd, Tokyo, Japan, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: RGB-19 is a proposed biosimilar to tocilizumab, a monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor. Results of a…
Abstract Number: 0310 • ACR Convergence 2025
Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
Annahita Keravala¹, Philip Conaghan², shanna jackson¹, sharmila Vijay¹, Thomas Chalberg³, Jeyanesh Tambiah⁴ and Laurie Halligan¹, ¹Genascence, Palo Alto, CA, ²University of Leeds, Leeds, United Kingdom, ³Genascence Corp, Palo Alto, CA, ⁴Genascence, San Diego, CA
Background/Purpose: IL-1 contributes significantly to osteoarthritis (OA) pathology, driving inflammation and cartilage degradation. Prior therapies targeting IL-1 have shown limited success due to inadequate drug…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].